ArticleBMC cancer2026
Longitudinal monitoring of circulating tumor cell dynamics for potential prediction of early recurrence and clinical outcomes after curative resection of hepatocellular carcinoma: a pilot study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) has a high recurrence rate even after curative hepatectomy. Circulating tumor cells (CTCs) have emerged as promising liquid biopsy biomarkers for minimal residual disease and early recurrence. This study evaluated longitudinal CTC dynamics and their prognostic significance in HCC patients undergoing curative resection.
methodsWe prospectively analyzed CTCs in 27 HCC patients at four time points: preoperatively, immediately postoperatively, and at 6 and 12 months after surgery. CTCs were defined as CD45⁻/CD146⁺/ASGPR⁺ using multicolor flow cytometry and immunofluorescence. Recurrence-free survival (RFS) and overall survival (OS) were assessed during a median 3.7-year follow-up. Control groups included 29 patients with non-malignant or non-HCC liver tumors and 8 healthy donors.
resultsPreoperative CTCs were detected in 48.2% of HCC patients (mean 0.46 cells/mL). Detection rates rose to 95% at 6 months and 100% at 12 months post-surgery. Persistent or rising postoperative CTCs were strongly associated with early recurrence (51.8% overall) and reduced RFS (p = 0.02) and OS (p = 0.05). No significant correlation was observed between CTC levels and tumor size or volume, AFP, or IL-6 levels.
conclusionsLongitudinal CTC monitoring provides an early and non-invasive indicator of recurrence risk and survival after curative HCC resection. Persistent CTCs may represent minimal residual disease and a potential therapeutic target for improving long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.